Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: Challenging its predictive value

Loredana Ruggeri, Antonella Mancusi, Marusca Capanni, Elena Urbani, Alessandra Carotti, Teresa Aloisi, Martin Stern, Daniela Pende, Katia Perruccio, Emanuela Burchielli, Fabiana Topini, Erika Bianchi, Franco Aversa, Massimo F. Martelli, Andrea Velardi

Research output: Contribution to journalArticlepeer-review

Abstract

We analyzed 112 patients with high-risk acute myeloid leukemia (61 in complete remission [CR]; 51 in relapse), who received human leukocyte-antigen (HLA)-haploidentical transplants from natural killer (NK) alloreactive (n = 51) or non-NK alloreactive donors (n = 61). NK alloreactive donors possessed HLA class I, killercell immunoglobulin-like receptor (KIR) ligand(s) which were missing in the recipients, KIR gene(s) for missing self recognition on recipient targets, and alloreactive NK clones against recipient targets. Transplantation from NK-alloreactive donors was associated with a significantly lower relapse rate in patients transplanted in CR (3% versus 47%) (P > .003), better event-free survival in patients transplanted in relapse (34% versus 6%, P = .04) and in remission (67% versus 18%, P = .02), and reduced risk of relapse or death (relative risk versus non-NK-alloreactive donor, 0.48; 95% CI, 0.29-0.78; P > .001). In all patients we tested the "missing ligand" model which pools KIR ligand mismatched transplants and KIR ligand-matched transplants from donors possessing KIR(s) for which neither donor nor recipient have HLA ligand(s). Only transplantation from NK-alloreactive donors is associated with a survival advantage.

Original languageEnglish
Pages (from-to)433-440
Number of pages8
JournalBlood
Volume110
Issue number1
DOIs
Publication statusPublished - Jul 1 2007

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: Challenging its predictive value'. Together they form a unique fingerprint.

Cite this